We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The drug comes with a boxed warning to alert patients and healthcare providers to the drug’s risk of serious and potentially fatal liver injury. Read More
The drug alongside androgen deprivation therapy provided a median of 40.4 months of metastasis-free survival compared to placebo and ADT’s 18.4 months, a Phase 3 trial showed. Read More
The condition is very serious for type 1 and type 2 diabetes patients and can lead to seizures, comas and even death if not treated properly. Read More
The condition is very serious for type 1 and type 2 diabetes patients and can lead to seizures, comas and even death if not treated properly. Read More
SCLC makes up around 15 percent of all cancer diagnoses and is the most aggressive form of lung cancer, with only six percent of patients surviving after five years. Read More
“The safety and efficacy of SGLT2 inhibitors have not been established in patients with type 1 diabetes, and FDA has not approved them for use in these patients,” the agency said. Read More
“EMA should ensure that there is a separation between those responsible for providing scientific advice to a medicine developer and those…involved in evaluating a marketing authorization application for the same medicine,” the ombudsman said. Read More